Effectiveness of bretylium tosylate against refractory ventricular arrhythmias.
D000200:Action Potentials / Q000187:drug effects; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001949:Bretylium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000187:drug effects; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009638:Norepinephrine / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects; D013610:Tachycardia / Q000188:drug therapy; D014105:Tosyl Compounds / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D001949:Bretylium Compounds; D014105:Tosyl Compounds; D009638:Norepinephrine